Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02429258 · ClinicalTrials.gov registry record · Phase 4
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 226
- Enrollment target
NCT02429258 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 226 participants.
The verdict
NCT02429258, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 226 participants
- Enrollment target
Study Summary
Effect of Dapagliflozin on 24-hour Blood Glucose in Type 2 Diabetes Patients Inadequately Controlled With Either Metformin Or Insulin
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Insulin
- DRUG Farxiga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02429258
The ClinicalTrials.gov registry entry for NCT02429258 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02429258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02429258 about?
NCT02429258 is a clinical study titled "Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin". Effect of Dapagliflozin on 24-hour Blood Glucose in Type 2 Diabetes Patients Inadequately Controlled With Either Metformin Or Insulin
What is the current status of trial NCT02429258?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 226 participants. The study started on 2015-05. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02429258?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Insulin (DRUG), Farxiga (DRUG).
Who is sponsoring clinical trial NCT02429258?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.